C-peptide vs REGN1033
Head-to-head comparison of C-peptide (Connecting peptide (C-peptide)) and REGN1033 (Trevogrumab (REGN1033)) — benefits, dosing, side effects, research data, and where to buy.
| Property | C-peptide | REGN1033 |
|---|---|---|
| Category | Pain Management | Muscle & Performance |
| Full Name | Connecting peptide (C-peptide) | Trevogrumab (REGN1033) |
| Molecular Weight | 3020.3 Da | ~150 kDa |
| Half-Life | ~20-30 min | ~2-3 weeks |
| Amino Acids | 31 | N/A |
| Typical Dose | no approved analgesic dose|research-only | 100-300 mg SC or equivalent trial dosing |
| Route | IV|subQ | Subcutaneous / Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 46 | 60 |
| Research Status | Pre-clinical | Clinical |
C-peptide Benefits
- ✓diabetic neuropathy research
- ✓nerve function support
- ✓possible analgesic effect
REGN1033 Benefits
- ✓myostatin blockade
- ✓lean-mass preservation
- ✓muscle hypertrophy support
- ✓catabolic-state countermeasure
C-peptide Dosing
0.5-1.0 mg/day in research|route varies by protocol
REGN1033 Dosing
SC or IV clinical-trial dosing|repeat every 2-4 weeks|dose escalation by study
C-peptide Side Effects
- ⚠injection-site reactions
- ⚠unknown long-term safety
REGN1033 Side Effects
- ⚠injection-site reactions
- ⚠headache
- ⚠fatigue
Research Overview
C-peptide
C-peptide is not an approved analgesic, but multiple studies have examined its effects on peripheral nerve blood flow and neuropathy outcomes. The strongest relevance is in diabetic neuropathic pain rather than migraine.
REGN1033
Human and animal studies indicate that myostatin neutralization can increase muscle size, though functional gains are often smaller than mass gains. Trevogrumab is part of the broader literature showing that selective myostatin inhibition can alter body composition in clinically meaningful ways.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.